Compare ARLO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | ANAB |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2018 | 2015 |
| Metric | ARLO | ANAB |
|---|---|---|
| Price | $14.43 | $48.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $20.67 | ★ $87.25 |
| AVG Volume (30 Days) | ★ 1.8M | 465.6K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.16 | 91.02 |
| EPS | ★ 0.16 | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $11.76 | N/A |
| Revenue Next Year | $5.56 | $69.42 |
| P/E Ratio | $91.87 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $11.05 | $30.27 |
| 52 Week High | $19.35 | $73.30 |
| Indicator | ARLO | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 63.63 | 46.60 |
| Support Level | $12.01 | $44.38 |
| Resistance Level | $15.19 | $51.94 |
| Average True Range (ATR) | 0.67 | 2.32 |
| MACD | 0.29 | 0.47 |
| Stochastic Oscillator | 88.29 | 53.73 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. Its cloud-based platform provides users with visibility, insight, and a powerful means to help protect and connect in real-time with the people and things that matter, from any location with a Wi-Fi or cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).